Request Your Free Survey Report Now:

"What Biotechs Want from CRO and CDMO Partnerships"

This report discusses the trends, tracking expectations across capacity, processing, and other demands.

Facing internal pressures alongside external ones, organizations are rethinking how they bring their therapeutics to market—including their choice of outsourcing partnerships with contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs). 

A recent survey from BioPharma Dive and Cytiva explored these trends, asking emerging biotechs about their current pipelines, intentions for the future, and expectations for selected partners. This survey report discusses those findings, tracking shifting sentiments and confidence in manufacturing capacity, processing, and other workflows. You’ll learn:

• Projected growth of manufacturing for CGTs, mABs, and novel molecules such as antibody drug conjugates
• Key barriers and challenges to manufacturing that are most concerning to biotech companies
• Where biotechs see the most and least value in outsourcing partnerships
• Top takeaways for CROs and CDMOs to consider when pursuing new prospects

Offered Free by: BioPharma Dive's studioID and Cytiva
See All Resources from: BioPharma Dive's studioID and Cytiva